400
Participants
Start Date
July 22, 2025
Primary Completion Date
November 30, 2028
Study Completion Date
February 28, 2029
4D-150 IVT (3E10 vg/eye)
If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1
EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Eylea (aflibercept) will be administered at applicable visits
NOT_YET_RECRUITING
New York Presbyterian Hospital - Columbia University Medical Center, New York
RECRUITING
Vitreoretinal Consultants of NY, Westbury
NOT_YET_RECRUITING
The Retina Care Center, Baltimore
RECRUITING
Cumberland Valley Retina Consultants, Hagerstown
RECRUITING
North Carolina Retina Associates, Cary
NOT_YET_RECRUITING
Carolina Eyecare, Mt. Pleasant
RECRUITING
Charleston Neuroscience Institute, LLC, Bluffton
NOT_YET_RECRUITING
Thomas Eye Group, Sandy Springs
RECRUITING
Retina Vitreous Associates of Florida, Tampa
NOT_YET_RECRUITING
ClearVista Clinical Research, Hudson
RECRUITING
Tennessee Retina, PC, Nashville
NOT_YET_RECRUITING
Cincinnati Eye Institute, Cincinnati
RECRUITING
Texas Retina Associate, Dallas
RECRUITING
Tyler Retina Consultants, Tyler
NOT_YET_RECRUITING
Southwest Retina Specialist - Panhandle Eye group, LLP, Amarillo
RECRUITING
Southwest Retina Consultants, Durango
RECRUITING
Rocky Mountain Retina Consultants, Salt Lake City
RECRUITING
Barnet Dulaney Perkins Eye Center, Sun City
RECRUITING
Retina Associates, Tucson
RECRUITING
Retina Consultants of Orange County, Fullerton
RECRUITING
West Coast Retina Medical Group, San Francisco
RECRUITING
Retinal Diagnostic Center, Campbell
RECRUITING
Pacific Northwest Retina, Silverdale
RECRUITING
Verum Research, LLC, Eugene
Lead Sponsor
4D Molecular Therapeutics
INDUSTRY